By Sabela Ojea
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.
The diabetes devices maker on Friday said the warning letter doesn't restrict its ability to produce, market, manufacture or distribute products. It doesn't require the recall of any products either.
In the letter the FDA mentioned non-conformities in manufacturing processes and the quality management system, the company said in a filing with the Securities and Exchange Commission.
DexCom said it takes the matters identified seriously and intends to continue to undertake certain corrections and corrective actions.
"Until the issues cited in the warning letter are resolved to the FDA's satisfaction, additional legal or regulatory action may be taken without further notice," the company said, adding that it can't give any assurances that the FDA will be satisfied with its response.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 07, 2025 17:20 ET (22:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。